 |
Indication & Dosage |
| |
| |
| Intravenous |
| METASTATIC COLORECTAL CANCER |
| Adult:
In combination with fluorouracil and folinic acid: 85 mg/m2 by IV infusion over 2-6 hr, dissolved in 250-500 ml of glucose 5%, every 2 wk. After recovery from toxicity, reduce dose to 65 mg/m2. Administer before fluoropyrimidines. |
| |
| Intravenous |
| STAGE III COLON CANCER |
| Adult:
As adjuvant therapy: 85 mg/m2 by IV infusion over 2-6 hr, dissolved in 250-500 ml of glucose 5%, every 2 wk; given for 12 cycles. After recovery from toxicity, reduce dose to 75 mg/m2. Administer before fluoropyrimidines. |
|
| |
|
| Precautions |
Should be administered under the supervision of an experienced cancer chemotherapy physician. Use appropriate precautions for handling and disposal. Monitor neurological status and dose should be reduced if symptoms are prolonged or severe. Monitor blood counts during treatment and courses should not be repeated until blood counts have recovered. Caution in elderly, moderate degrees of renal impairment. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Fatigue, fever, pain, headache, insomnia, nausea, diarrheoa, vomiting, abdominal pain, constipation, anorexia, stomatitis, anemia, thrombocytopenia, leukopenia, aspartate and alanine transaminases increased, total bilirubin increased, peripheral neuropathy, back pain, dyspnoea, cough, oedema, chest pain, peripheral oedema, flushing , thromboembolism, dizziness, rash, alopecia , hand-foot syndrome dehydration, hypokalaemia, dyspepsia, taste perversion, flatulence, mucositis, gastroesophageal reflux, dysphagia, dysuria, neutropenia, inj site reaction, rigors, arthralgia, abnormal lacrimation, serum creatinine increased, rhinitis, epistaxis, pharyngitis, pharyngolaryngeal dysesthesia, allergic reactions, hiccup. |
| |
|
| Adverse Drug Reactions |
Anaphylaxis, pulmonary fibrosis. |
| |
|
| Interactions |
May decrease plasma levels of digoxin. May increase risk of toxicity with nephrotoxic drugs. When administered as sequential infusions, taxane derivatives (docetaxel, paclitaxel) should be administered before oxaliplatin to limit myelosuppression and enhance efficacy. |
| |
|
|
|
